NYSEARCA:HTBX - NYSE Arca - US42237K4094 - Common Stock
NYSEARCA:HTBX (5/2/2022, 8:04:01 PM)
2.38
+0.01 (+0.42%)
The current stock price of HTBX is 2.38 null. In the past month the price decreased by -22.98%. In the past year, price decreased by -61.92%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.83 | 342.01B | ||
AMGN | AMGEN INC | 14.32 | 152.57B | ||
GILD | GILEAD SCIENCES INC | 13.34 | 128.71B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1720.21 | 128.25B | ||
REGN | REGENERON PHARMACEUTICALS | 13.32 | 64.50B | ||
ARGX | ARGENX SE - ADR | 336.79 | 39.07B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.19B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.55B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.62B | ||
NTRA | NATERA INC | N/A | 20.46B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.19B | ||
BIIB | BIOGEN INC | 7.34 | 17.70B |
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Morrisville, North Carolina and currently employs 49 full-time employees. The company went IPO on 2013-07-24. The Company’s gp96 platform is designed to activate the immune system. This platform has applications in cancer and infectious disease. Its platform leverages gp96’s role as a natural molecular warning system that presents antigens to the immune system. The firm also develops ANTHIM, a treatment for inhalation anthrax. ANTHIM is used in the United States and Canada and sold under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. ANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIM’s toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage. ANTHIM is supplied as single-dose vials for Intravenous Therapy (IV) infusion. ANTHIM is indicated in adult and pediatric patients.
HEAT BIOLOGICS INC
627 Davis Drive, Suite 400
Morrisville NORTH CAROLINA 27560 US
CEO: Jeffrey Wolf
Employees: 49
Company Website: http://www.heatbio.com/
Phone: 19192407133.0
The current stock price of HTBX is 2.38 null. The price increased by 0.42% in the last trading session.
The exchange symbol of HEAT BIOLOGICS INC is HTBX and it is listed on the NYSE Arca exchange.
HTBX stock is listed on the NYSE Arca exchange.
10 analysts have analysed HTBX and the average price target is 11.6 null. This implies a price increase of 387.5% is expected in the next year compared to the current price of 2.38. Check the HEAT BIOLOGICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
HEAT BIOLOGICS INC (HTBX) has a market capitalization of 61.05M null. This makes HTBX a Micro Cap stock.
HEAT BIOLOGICS INC (HTBX) currently has 49 employees.
HEAT BIOLOGICS INC (HTBX) has a support level at 2.33 and a resistance level at 2.38. Check the full technical report for a detailed analysis of HTBX support and resistance levels.
The Revenue of HEAT BIOLOGICS INC (HTBX) is expected to grow by 128.57% in the next year. Check the estimates tab for more information on the HTBX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HTBX does not pay a dividend.
HEAT BIOLOGICS INC (HTBX) will report earnings on 2022-05-17, before the market open.
HEAT BIOLOGICS INC (HTBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.41).
ChartMill assigns a fundamental rating of 4 / 10 to HTBX. While HTBX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months HTBX reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS increased by 9.62% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -1658.78% | ||
ROA | -28.99% | ||
ROE | N/A | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to HTBX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -23.7% and a revenue growth 128.57% for HTBX